Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung… Read more
Apollomics Inc. Class A Ordinary Shares (APLM) - Net Assets
Latest net assets as of September 2025: $-4.40 Million USD
Based on the latest financial reports, Apollomics Inc. Class A Ordinary Shares (APLM) has net assets worth $-4.40 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.12 Million) and total liabilities ($15.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.40 Million |
| % of Total Assets | -39.55% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Apollomics Inc. Class A Ordinary Shares - Net Assets Trend (2019–2024)
This chart illustrates how Apollomics Inc. Class A Ordinary Shares's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Apollomics Inc. Class A Ordinary Shares (2019–2024)
The table below shows the annual net assets of Apollomics Inc. Class A Ordinary Shares from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.86 Million | -88.20% |
| 2023-12-31 | $41.23 Million | +109.20% |
| 2022-12-31 | $-448.12 Million | -110.52% |
| 2021-12-31 | $-212.86 Million | -66.39% |
| 2020-12-31 | $-127.93 Million | -110.69% |
| 2019-12-31 | $-60.72 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Apollomics Inc. Class A Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 63409200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.23% |
| Other Comprehensive Income | $3.44 Million | 70.62% |
| Other Components | $702.24 Million | 14437.52% |
| Total Equity | $4.86 Million | 100.00% |
Apollomics Inc. Class A Ordinary Shares Competitors by Market Cap
The table below lists competitors of Apollomics Inc. Class A Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NORTHERN FREEGOLD
F:8N6
|
$10.57 Million |
|
Vraj Iron and Steel Ltd
NSE:VRAJ
|
$10.58 Million |
|
Ion Video Ltd
AU:IOV
|
$10.59 Million |
|
Galileo Mining Ltd
AU:GAL
|
$10.59 Million |
|
Reyna Silver Corp
OTCQB:RSNVF
|
$10.57 Million |
|
SKAKO A/S
CO:SKAKO
|
$10.56 Million |
|
Freeman Gold Corp
OTCQB:FMANF
|
$10.56 Million |
|
Hankukpackage Co. Ltd
KQ:037230
|
$10.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apollomics Inc. Class A Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 41,234,000 to 4,864,000, a change of -36,370,000 (-88.2%).
- Net loss of 53,858,000 reduced equity.
- Other comprehensive income decreased equity by 23,281,000.
- Other factors increased equity by 40,769,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-53.86 Million | -1107.28% |
| Other Comprehensive Income | $-23.28 Million | -478.64% |
| Other Changes | $40.77 Million | +838.18% |
| Total Change | $- | -88.20% |
Book Value vs Market Value Analysis
This analysis compares Apollomics Inc. Class A Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-69.96 | $19.50 | x |
| 2020-12-31 | $-147.40 | $19.50 | x |
| 2021-12-31 | $-245.24 | $19.50 | x |
| 2022-12-31 | $-516.29 | $19.50 | x |
| 2023-12-31 | $55.42 | $19.50 | x |
| 2024-12-31 | $5.25 | $19.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apollomics Inc. Class A Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1107.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27201.01%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 2.69x
- Recent ROE (-1107.28%) is below the historical average (-254.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-39.83 Million |
| 2020 | 0.00% | -4070.73% | 0.01x | 0.00x | $-62.03 Million |
| 2021 | 0.00% | -4739850.00% | 0.00x | 0.00x | $-73.51 Million |
| 2022 | 0.00% | -74554.49% | 0.00x | 0.00x | $-196.00 Million |
| 2023 | -418.59% | -21023.26% | 0.01x | 1.34x | $-176.72 Million |
| 2024 | -1107.28% | -27201.01% | 0.02x | 2.69x | $-54.34 Million |
Industry Comparison
This section compares Apollomics Inc. Class A Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apollomics Inc. Class A Ordinary Shares (APLM) | $-4.40 Million | 0.00% | N/A | $10.57 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |